Lexicon Pharmaceuticals Inc
NASDAQ: LXRX
$1.69
+$0.05 (+3.0%)
Closing Price on September 19, 2024
LXRX Articles
ThinkstockThursday may have been a mixed day in the markets with a gain in the S&P 500 and a drop in the Dow, but there are many stocks with big moves or big trading volume in Thursday’s...
Published:
We are seeing many key movers in the BioHealth space today. Biotech stocks and drug stocks are often more volatile than other sectors. Today’s BioHealth Business Daily includes the key moves...
Published:
Last Updated:
If you think you are alone in noticing that the markets have held up extremely well, you better take a look and see what managers and officers of public companies are doing on capital raises. There...
Published:
Last Updated:
Biophama companies are horrible investments at least 90% of the time because they are gambles on the IQs of small groups of scientists and the whims of the FDA. Poniard Pharmaceuticals (PARD) and...
Published:
These are this morning’s top pre-market day trader alert stocks. We have more color and more detail on price and volume analysis linked through to each at VSInvestor.com: Best Buy Co. (NYSE: BBY)...
Published:
Last Updated:
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) has announced that dosing has commenced in its Phase IIa clinical trial with LX6171. This is an oral drug candidate that is implied for the treatment of...
Published:
(AA) An ALCOA bid from BHP may be kindled according to numerous M&A reports.(ADVNA) Advanta trades ex-split to reflect a 3-2 stock split.(AGU) Agrium said earnings will be at or above the upper...
Published:
Lexicon Pharmaceuticals, Inc. (LXRX-NASDAQ) is a biotech company that many have not heard of, and those who do know it may have a painful history from it. Anyone who got in the stock over the last...
Published: